Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-21

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study the diagnostic accuracy of a diagnostic tool for the diagnosis of post-capillary pulmonary hypertension will be investigated.

The diagnostic tool was designed based on artificial intelligence, using machine learning on a database of 344 patients with group 1 or group 2 pulmonary hypertension. The tool uses 20 non-invasive parameters which are derived from laboratory results, ECG, echocardiography and spirometry. Based on these parameters, the predictive tool estimates the probability of group 2 pulmonary hypertension.

During this clinical study, patients with an intermediate or high suspicion of pulmonary hypertension, with an indication for a diagnostic right heart catheterization, will be included. Patients with risk factors for group 3, 4 or 5 pulmonary hypertension will be excluded.

The necessary parameters to run the predictive model will be extracted from the patients medical file. Patients will undergo a standard of care right heart catheterization (gold standard). Afterwards the results of the predictive model will be compared to those of the right heart catheterization, to allow the assessment of the sensitivity, specificity, positive and negative predictive value of the predictive tool.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies

NCT02959723

Idiopathic Pulmonary Arterial Hypertension

UNKNOWN

3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension

NCT02799979

Pulmonary Arterial Hypertension

UNKNOWN

Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure

NCT01545180

Heart Failure Post-capillary Pulmonary Hypertension

COMPLETED

Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism

NCT06183944

Pulmonary Embolism

RECRUITING

Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography

NCT01829672

Pulmonary Arterial Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension Pulmonary Arterial Hypertension HFpEF - Heart Failure With Preserved Ejection Fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optiek predictive model

Patient data will be extracted to run the predictive model, which will estimate the probability of group 2 pulmonary hypertension. However the results of the model will have no diagnostic or therapeutic implications in this phase of the investigation.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
2. Male or female patients of at least 18 years old.
3. Availability of the results of a basic work-up:

1. Medical history, demographic information and clinical information (including BMI)
2. Laboratory tests including hemoglobin, hematocrit and uric acid
3. ECG
4. Pulmonary function tests
5. Echocardiography
4. Intermediate to high probability of PH based on echocardiography according to the 2022 ESC/ERS guidelines (see Figure 2 and Table 2). (1)
5. Indication for RHC according to ESC/ERS 2022 guidelines. (1)

Exclusion Criteria

1. Evidence of significant pulmonary comorbidity based on abnormal pulmonary function tests (FEV1 below 60%) or aberrant lung parenchyma more than mild on radiological imaging.
2. Perfusion defects and ventilation mismatch on a recent V/Q scan.
3. Arterial perfusion defects on a recent thoracic CT angiography.
4. The following comorbidities associated with group 1 PH:

1. Connective tissue disease
2. HIV infection
3. Portal hypertension
4. Congenital heart disease
5. The following comorbidities associated with group 5 PH:

1. Hematological disorders such as chronic hemolytic anemia or myeloproliferative disorders.
2. Systemic and metabolic disorders such as pulmonary Langerhans cell histiocytosis, Gaucher disease, glycogen storage diseases, neurofibromatosis or sarcoidosis.
3. Chronic renal failure (eGFR below 30 ml/min) with or without hemodialysis
4. Fibrosing mediastinitis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No